Let us start with the fundamental reality that most political debates conveniently ignore. Across the OECD, there is no evidence that switching from a publicly administered healthcare system to a privately dominated system improves efficiency. In fact, the evidence points firmly in the opposite direction. A comprehensive study published in The European Journal of Health Economics in 2025 analysed performance data across 38 OECD countries and reached a striking conclusion: overall efficiency increases with the public share of financing . The more public funding a healthcare system has, the more efficiently it tends to deliver care. This finding challenges the assumption that private sector competition automatically drives down costs and improves quality. Private insurance systems come with administrative overhead, marketing budgets, profit margins, and executive salaries, all of which add zero clinical value but add significantly to the total bill. Tax-funded systems, by contrast, channel a much higher proportion of every euro directly into patient care.
This is not just academic theory. A major report published in April 2026 by the Institute for Public Policy Research, one of the United Kingdom's most influential think tanks, analysed healthcare systems across 22 high-income countries and found that tax-funded systems are demonstrably cheaper for patients. In the United Kingdom, which operates a predominantly tax-funded National Health Service, households spend just 2.6 percent of their income on out-of-pocket health costs. In insurance-based systems, that figure jumps to 3.5 percent . That difference might sound small, but for a household earning the European median income, it represents hundreds of euros every year that could go toward rent, food, or savings. The same report found that administrative costs consume only 2.2 percent of health spending in tax-funded systems, compared to 3.5 percent in insurance-based systems . That is a massive efficiency gap. Every percentage point saved on paperwork is a percentage point that can be spent on doctors, nurses, medicines, and hospital beds.
So why does private healthcare continue to grow across Europe? Why are millions of people voluntarily paying for insurance or paying directly out of pocket when public systems exist? The answer lies in waiting times, access to innovation, and the specific services that public systems do not fully cover. A comparative analysis of Europe's largest healthcare systems, including Germany, France, Italy, Spain, the Netherlands, and the United Kingdom, reveals a complex picture of trade-offs . Germany and the Netherlands, which operate social health insurance models, excel at providing short waiting times and rapid access to new treatments and technologies. If you need an MRI scan or a cutting-edge cancer therapy, you are likely to get it faster in Berlin or Amsterdam than in Madrid or Manchester. But speed comes at a cost. Insurance premiums in these systems are mandatory, typically deducted directly from your salary, and they are not cheap. Out-of-pocket payments, copayments, and deductibles add another layer of expense. The system is efficient, but it is not free.
On the other end of the spectrum, countries like Spain, Italy, and the United Kingdom offer genuinely low-cost care at the point of delivery. You walk into a public hospital, receive treatment, and walk out without handing over a credit card. The problem is that you might wait. Waiting lists in the United Kingdom and Spain have grown significantly, with patients in some regions waiting months for specialist appointments or elective surgeries. Italy faces a particularly stark divide: the northern regions generally provide faster and higher-quality public care, while the southern regions struggle with delays, shortages, and lower standards . This geographic inequality is a hidden cost that does not show up on any invoice. If you live in Calabria, your public healthcare might require you to travel north, pay for accommodation, or simply wait in pain. Those are real costs, even if no hospital bills you directly.
France occupies an interesting middle ground. The French system combines mandatory public insurance with copayments and a thriving supplementary private insurance market. Everyone is covered by the public system, but you pay a portion of each doctor's visit, each prescription, and each hospital stay. Most people purchase supplementary health insurance, known as a mutuelle, to cover these copayments. By law, this supplementary insurance is widely available, and around 80 percent of the population holds it . The result is a system that provides excellent access and relatively short waiting times while spreading costs across both taxes and private premiums. But it is not cheap. French healthcare spending is among the highest in Europe as a percentage of GDP. The costs are simply distributed differently than in a purely tax-funded model.
The real financial trap for Europeans lies in the gaps between what public systems cover and what they do not. Across the OECD, coverage varies dramatically depending on the type of service. In nearly all European countries, inpatient hospital care is the most comprehensively covered service, with government or compulsory insurance paying for 89 percent of costs on average . In Sweden, Norway, Iceland, Estonia, and Romania, coverage for acute inpatient care approaches 100 percent. But outpatient medical care tells a different story. In Latvia, Israel, Portugal, Italy, and Korea, public coverage for outpatient care falls below 60 percent . This means that if you need to see a specialist, undergo diagnostic tests, or receive ongoing treatment for a chronic condition outside of a hospital setting, you may be paying a significant share of those costs yourself.
Dental care is where the public system's limitations become truly painful. On average across OECD countries, less than one-third of dental care costs are covered by government or compulsory insurance . This is why dental care has become a flashpoint for private sector involvement. In Spain, for example, the share of dental practices run by private dental service organisations doubled between 2015 and 2018 . These organisations are not charities. They exist to make profits, and those profits come out of your pocket. If you need a root canal, a crown, or orthodontic work for your children, you are likely paying for most of it yourself, regardless of which European country you live in. The same pattern holds for pharmaceuticals, though to a lesser degree. France and Germany provide generous public coverage for prescription drugs, around 82 to 83 percent, while Poland and other Eastern European countries leave patients to cover more than 65 percent of their medicine costs out of pocket .
This patchwork of coverage creates a confusing and often expensive reality for ordinary Europeans. You might assume that because your country has universal healthcare, you are protected from major medical expenses. But universal does not mean unlimited. It does not mean free. It means everyone has access to a basic package of services, but the definition of basic varies widely. In Italy, for instance, the government allocated €50 million in 2025 to help regions reduce waiting times, but this is a response to a crisis, not a solution to the underlying problem of underfunding . The Italian budget also increased funding for mental health support and obesity prevention, acknowledging that these areas have been neglected. But these targeted investments, while welcome, do not change the fundamental reality that patients who want faster access or broader coverage must often turn to private alternatives.
The private insurance market itself is complex and varies dramatically by country. In the United Kingdom, about 22 percent of the population has some form of private health insurance, representing a total market value of £11.4 billion in 2022 . However, private insurance in the UK typically does not cover primary care or outpatient medicines. It is largely focused on acute hospital services, allowing patients to bypass NHS waiting lists for surgeries and specialist treatments. In Italy, only about 10 percent of the population has complementary private insurance, usually provided through employer plans, and most of these plans do not cover pharmaceuticals . Yet despite low insurance coverage, around 25 percent of Italy's total drug spending comes directly out of patients' pockets, typically for prescription medications that are not publicly reimbursed. In France, supplementary health insurance is nearly universal, but it primarily covers copayments for publicly reimbursed services rather than providing access to services outside the public system entirely.
What does this mean for your daily life and your monthly budget? It means that the question of whether public or private healthcare is cheaper has no single answer. It depends on where you live, how healthy you are, what kind of care you need, and how much you value your time. If you are young, healthy, and rarely see a doctor, the public system is almost certainly cheaper. You pay your taxes or your social contributions, but you avoid the additional cost of private insurance premiums. If you have a chronic condition that requires frequent specialist visits, you face a trade-off. Public systems will cover much of the cost, but you may endure long waits and limited choices. Private insurance can shorten those waits, but you will pay for that speed through higher premiums and possibly higher out-of-pocket costs.
The hidden costs are the ones that never appear on a receipt. The day you take off work to wait for a public appointment that gets rescheduled. The six months you spend in pain while on a waiting list for a hip replacement. The anxiety of not knowing whether a worrying symptom is serious while you wait weeks for a diagnostic test. These are real costs, and they fall disproportionately on people who cannot afford to pay their way to the front of the line. Private healthcare is not just about money. It is about time, comfort, and peace of mind. For those who can afford it, private insurance buys certainty. For those who cannot, the public system is a lifeline, even with its flaws.
The IPPR report's findings are particularly relevant here. The researchers concluded that tax-funded systems have clear advantages in terms of patient costs and administrative efficiency, and they found no evidence that insurance-based systems outperform them on measures of capacity, access, quality, equity, and efficiency . However, they also noted that the NHS's poor performance compared to other countries is driven by chronic underinvestment, not by the funding model itself. Capital investment in the NHS, spending on beds, diagnostic equipment, and hospital buildings, is currently lower than it was in 2010 . This is a political choice, not an inherent flaw of tax-funded healthcare. The same study found that the real reason some public systems struggle is not that they are public, but that they are underfunded. Insurance-based systems like Germany's and the Netherlands' receive higher levels of funding per capita, which allows them to maintain shorter waiting times and better infrastructure. If public systems received comparable funding, the performance gap might disappear.
The European Commission is increasingly aware of these dynamics. In December 2025, it unveiled the European Affordable Housing Plan, acknowledging that housing is now a structural risk to economic stability. Healthcare faces a similar reckoning. The WHO European Health Information Gateway tracks public sector health expenditure as a percentage of total health expenditure across the continent, and the numbers reveal vast differences . Some countries rely almost entirely on public funding, while others have significant private components. These differences are not accidents of history. They are policy choices, and they have direct consequences for how much you pay when you are sick.
The trend toward privatisation is not inevitable, but it is real. As public systems face budget pressures, waiting lists grow, and populations age, more Europeans are turning to private alternatives. This creates a dangerous feedback loop. When wealthier patients leave the public system, they take their political influence with them. The public system becomes increasingly the domain of the poor, the elderly, and the chronically ill, groups with less political power. This makes it easier for governments to underfund the public system further, which drives more people to private insurance, which further erodes the political constituency for strong public healthcare. This is not a conspiracy theory. It is a well-documented pattern observed in countries that have moved from predominantly public to mixed systems.
The pharmaceutical market adds another layer of complexity. Manufacturers of new medicines are increasingly looking beyond traditional public payer routes to secure patient access, exploring private health insurance and out-of-pocket payment pathways . This means that cutting-edge treatments, the ones that offer the best outcomes for serious conditions, are often available first or exclusively through private channels. Public systems, constrained by budgets and formal health technology assessment processes, are slower to adopt new drugs. If you have a rare cancer or a complex autoimmune condition, the difference between public and private could be measured in months of waiting, or in access versus no access at all. That is a cost that cannot be quantified in euros.
So which is actually cheaper? The honest answer is that public healthcare is cheaper for society as a whole, but private healthcare can be cheaper for an individual in specific circumstances. Public systems spread risk across the entire population, achieving economies of scale and eliminating the profit motive. They are more efficient at delivering basic, high-volume care to large numbers of people. But they are often slower, less convenient, and less responsive to individual preferences. Private systems allow you to pay for speed, choice, and comfort, but they cost more for the same clinical outcome when you account for all the administrative overhead and profit margins. The evidence from the OECD is clear: overall efficiency increases with the public share of financing . For every euro you put into a public system, you get more healthcare than you would from a private system. But that healthcare may not be delivered exactly when and how you want it.
The decision you face as a European consumer is not about choosing one system exclusively. Most people live in mixed realities. You rely on the public system for catastrophic events, hospitalisations, and primary care. You pay out of pocket for dental work, glasses, and maybe physiotherapy. You might buy private insurance to skip waiting lists for elective surgery or to access a private room if you are hospitalised. Understanding the true costs of each component allows you to make rational decisions about where to spend your money. The person who buys comprehensive private insurance but never uses it is wasting money. The person who relies entirely on the public system but needs a hip replacement and cannot wait two years is suffering unnecessarily. The optimal strategy lies somewhere in the middle, calibrated to your health, your finances, and the specific strengths and weaknesses of the system in your country.